Anti-inflammatory Effect of Agaricus Blazei Murill in Inflammatory Bowel Disease (IBD)

Oslo University Hospital100 enrolled

Overview

Examine whether daily oral ingestion of a immunomodulatory mushroom extract (AndoSanTM) in patients with ulcerative colitis (UC) and Crohn's disease (CD), experience clinical, biochemical and genetical improvement in their disease. A prospective randomised study comparing the mushroom extract with placebo.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Enrollment

100

Conditions

Ulcerative Colitis Crohn's Disease Inflammatory Bowel Disease

Interventions

AndoSanDIETARY_SUPPLEMENT

AndoSan 30 ml x 2 for 21 days

Sugar ExtractDIETARY_SUPPLEMENT

Sham comparator

Eligibility

Sex: ALLMin age: 18 YearsMax age: 60 Years

Medical Language ↔ Plain English

Inclusion Criteria: * moderate disease Exclusion Criteria: * serious disease, * biological treatment, * pregnancy.

Locations (1)

Oslo University Hospital, Ulleval

Oslo, Norway

Outcomes

Primary Outcomes

Reduction in biochemical blood parameters (pro-inflammatory cytokines)

Time frame: 21 days

Secondary Outcomes

Reduction of calprotectin in feces.

Time frame: 21 days

Clinical symptom score.

Time frame: 21 days

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.